| Implementing outcomes-based managed entry agreements for rare disease treatments: nusinersen and tisagenlecleucel KM Facey, J Espin, E Kent, A Link, E Nicod, A O’Leary, E Xoxi, ... Pharmacoeconomics 39, 1021-1044, 2021 | 51 | 2021 |
| Telementoring with project ECHO: a pilot study in Europe CN Cheallaigh, A O’Leary, S Keating, A Singleton, S Heffernan, E Keenan, ... BMJ innovations 3 (3), 2017 | 49 | 2017 |
| Generic medicines and generic substitution: contrasting perspectives of stakeholders in Ireland A O’Leary, C Usher, M Lynch, M Hall, L Hemeryk, S Spillane, P Gallagher, ... BMC research notes 8, 1-10, 2015 | 45 | 2015 |
| The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1 J Kieran, S Schmitz, A O'Leary, C Walsh, C Bergin, S Norris, M Barry Clinical infectious diseases 56 (2), 228-235, 2013 | 38 | 2013 |
| Introduction and utilization of high priced HCV medicines across Europe; implications for the future W De Bruijn, C Ibáñez, P Frisk, H Bak Pedersen, A Alkan, ... Frontiers in pharmacology 7, 197, 2016 | 33 | 2016 |
| Determinants of HIV outpatient service utilization: a systematic review A Brennan, D Morley, AC O’Leary, CJ Bergin, M Horgan AIDS and Behavior 19, 104-119, 2015 | 30 | 2015 |
| Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals LT Nguyen, E Gray, J Dean, M Carr, J Connell, CD Gascun, LA Nguyen, ... Antiviral therapy 20 (8), 865-869, 2015 | 29 | 2015 |
| Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study JA Kieran, S Norris, A O’Leary, C Walsh, R Merriman, D Houlihan, ... BMC infectious diseases 15, 1-9, 2015 | 28 | 2015 |
| Pharmacoeconomic evaluation in Ireland: a review of the process L Tilson, A O’Leary, C Usher, M Barry Pharmacoeconomics 28, 307-322, 2010 | 28 | 2010 |
| COVID-19 related regulatory change for pharmacists–The case for its retention post the pandemic M Lynch, AC O'Leary Research in Social and Administrative Pharmacy 17 (1), 1913-1919, 2021 | 24 | 2021 |
| Incorporating single‐arm evidence into a network meta‐analysis using aggregate level matching: assessing the impact J Leahy, H Thom, JP Jansen, E Gray, A O'Leary, A White, C Walsh Statistics in medicine 38 (14), 2505-2523, 2019 | 23 | 2019 |
| Comorbidities and cardiovascular risk factors in an aged cohort of HIV-infected patients on antiretroviral treatment in a Spanish hospital in 2016 C Fontela, J Castilla, R Juanbeltz, I Martínez-Baz, M Rivero, A O’Leary, ... Postgraduate medicine 130 (3), 317-324, 2018 | 22 | 2018 |
| Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population R Juanbeltz, J Castilla, I Martínez-Baz, A O’Leary, M Sarobe, ... Quality of Life Research 28, 1477-1484, 2019 | 21 | 2019 |
| The impact of individual patient data in a network meta‐analysis: An investigation into parameter estimation and model selection J Leahy, A O'Leary, N Afdhal, E Gray, S Milligan, MH Wehmeyer, C Walsh Research synthesis methods 9 (3), 441-469, 2018 | 21 | 2018 |
| Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients V Gimeno-Ballester, J Mar, A O’Leary, R Adams, R San Miguel Expert Review of Gastroenterology & Hepatology 11 (1), 85-93, 2017 | 20 | 2017 |
| Generic substitution of antiretrovirals: patients’ and health care providers’ opinions JA Kieran, E O’Reilly, S O’Dea, C Bergin, A O’Leary International journal of STD & AIDS 28 (12), 1239-1246, 2017 | 18 | 2017 |
| Treatment of Kaposi’s sarcoma with liposomal doxorubicin C Bergin, A O’Leary, C McCreary, K Sabra, F Mulcahy American journal of health-system pharmacy 52 (18), 2001-2004, 1995 | 18 | 1995 |
| The role of hepatitis C virus core antigen testing in the era of direct acting antiviral therapies: what we can learn from the protease inhibitors LT Nguyen, E Gray, A O'Leary, M Carr, CF De Gascun, ... PLoS One 11 (10), e0163900, 2016 | 17 | 2016 |
| High mortality during direct acting antiviral therapy for hepatitis C patients with Child’s C cirrhosis: Results of the Irish Early Access Programme E Gray, A O’Leary, S Stewart, C Bergin, M Cannon, G Courtney, ... Journal of Hepatology 65 (2), 446-448, 2016 | 15 | 2016 |
| Understanding the factors influencing community pharmacist retention–A qualitative study M Lynch, AC O'Leary Exploratory research in clinical and social pharmacy 12, 100329, 2023 | 14 | 2023 |
